BARDA awards five contracts to support MCM studies network

The Biomedical Advanced Research and Development Authority recently awarded five contracts in support of the Medical Countermeasure Clinical Studies Network that will generate trial data to evaluate countermeasures.

BARDA awarded the contracts to Technical Resources International, Inc., Rho Federal Systems Division, Inc., PPD Development, The EMMES Corporation and Clinical Research Management, Inc. The indefinite delivery, indefinite quantity contracts will enable the five companies to evaluate MCMs like diagnostics, therapeutics, medical devices and vaccines, Global Biodefense reports.

"We look forward to working with BARDA to evaluate new treatments for medical conditions that could have devastating impacts on many people," David Hoover, the program director for ClinicalRM, said. "New treatments are vitally important for improved management of infectious diseases and exposures to a broad range of toxic agents."

The awardees signed two-year contracts that include three one-year options and are worth a maximum value of $100 million. In return, the companies will provide a full range of services, including statistical expertise, protocol development, project management, study design, reporting, data collection and data analysis, according to Global Biodefense.

"We are excited at the prospect of deploying our world-class scientific expertise, innovative solutions, cutting-edge technology, flexible resources and operational efficiencies to help protect public health and the nation's health security," Paul Colvin, the executive vice president of clinical development at PPD, said.

The studies performed by the network will clinically evaluate chemical, biological, radiological and nuclear countermeasures, in addition to pandemic influenza and emerging infectious disease countermeasures. The work may include Phase I, II, III, IV studies or combinations of multiple phases, Global Biodefense reports.